160 related articles for article (PubMed ID: 16651619)
1. Mortalin-based cytoplasmic sequestration of p53 in a nonmammalian cancer model.
Walker C; Böttger S; Low B
Am J Pathol; 2006 May; 168(5):1526-30. PubMed ID: 16651619
[TBL] [Abstract][Full Text] [Related]
2. Genotoxic stress-induced expression of p53 and apoptosis in leukemic clam hemocytes with cytoplasmically sequestered p53.
Böttger S; Jerszyk E; Low B; Walker C
Cancer Res; 2008 Feb; 68(3):777-82. PubMed ID: 18245478
[TBL] [Abstract][Full Text] [Related]
3. Cytoplasmic sequestration of the tumor suppressor p53 by a heat shock protein 70 family member, mortalin, in human colorectal adenocarcinoma cell lines.
Gestl EE; Anne Böttger S
Biochem Biophys Res Commun; 2012 Jun; 423(2):411-6. PubMed ID: 22683628
[TBL] [Abstract][Full Text] [Related]
4. Patterns of p53, p73 and mortalin gene expression associated with haemocyte polyploidy in the soft-shell clam, Mya arenaria.
Siah A; Delaporte M; Pariseau J; McKenna P; Berthe FC
J Invertebr Pathol; 2008 Jun; 98(2):148-52. PubMed ID: 18407289
[TBL] [Abstract][Full Text] [Related]
5. Mass culture and characterization of tumor cells from a naturally occurring invertebrate cancer model: applications for human and animal disease and environmental health.
Walker C; Böttger SA; Mulkern J; Jerszyk E; Litvaitis M; Lesser M
Biol Bull; 2009 Feb; 216(1):23-39. PubMed ID: 19218489
[TBL] [Abstract][Full Text] [Related]
6. Restoration of p53 functions by suppression of mortalin-p53 sequestration: an emerging target in cancer therapy.
Shankaranarayana AH; Meduri B; Pujar GV; Hariharapura RC; Sethu AK; Singh M; Bidye D
Future Med Chem; 2023 Nov; 15(22):2087-2112. PubMed ID: 37877348
[TBL] [Abstract][Full Text] [Related]
7. Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.
Grover A; Priyandoko D; Gao R; Shandilya A; Widodo N; Bisaria VS; Kaul SC; Wadhwa R; Sundar D
Int J Biochem Cell Biol; 2012 Mar; 44(3):496-504. PubMed ID: 22155302
[TBL] [Abstract][Full Text] [Related]
8. Mortalin inhibitors sensitize K562 leukemia cells to complement-dependent cytotoxicity.
Pilzer D; Saar M; Koya K; Fishelson Z
Int J Cancer; 2010 Mar; 126(6):1428-35. PubMed ID: 19739077
[TBL] [Abstract][Full Text] [Related]
9. Haemocytic leukemia in Prince Edward Island (PEI) soft shell clam (Mya arenaria): spatial distribution in agriculturally impacted estuaries.
Muttray A; Reinisch C; Miller J; Ernst W; Gillis P; Losier M; Sherry J
Sci Total Environ; 2012 May; 424():130-42. PubMed ID: 22425172
[TBL] [Abstract][Full Text] [Related]
10. Expression of homologues for p53 and p73 in the softshell clam (Mya arenaria), a naturally-occurring model for human cancer.
Kelley ML; Winge P; Heaney JD; Stephens RE; Farell JH; Van Beneden RJ; Reinisch CL; Lesser MP; Walker CW
Oncogene; 2001 Feb; 20(6):748-58. PubMed ID: 11314008
[TBL] [Abstract][Full Text] [Related]
11. Identification and functional characterization of nuclear mortalin in human carcinogenesis.
Ryu J; Kaul Z; Yoon AR; Liu Y; Yaguchi T; Na Y; Ahn HM; Gao R; Choi IK; Yun CO; Kaul SC; Wadhwa R
J Biol Chem; 2014 Sep; 289(36):24832-44. PubMed ID: 25012652
[TBL] [Abstract][Full Text] [Related]
12. Reconstitution of the mitochondrial Hsp70 (mortalin)-p53 interaction using purified proteins--identification of additional interacting regions.
Iosefson O; Azem A
FEBS Lett; 2010 Mar; 584(6):1080-4. PubMed ID: 20153329
[TBL] [Abstract][Full Text] [Related]
13. Selective toxicity of MKT-077 to cancer cells is mediated by its binding to the hsp70 family protein mot-2 and reactivation of p53 function.
Wadhwa R; Sugihara T; Yoshida A; Nomura H; Reddel RR; Simpson R; Maruta H; Kaul SC
Cancer Res; 2000 Dec; 60(24):6818-21. PubMed ID: 11156371
[TBL] [Abstract][Full Text] [Related]
14. Activation of wild type p53 function by its mortalin-binding, cytoplasmically localizing carboxyl terminus peptides.
Kaul SC; Aida S; Yaguchi T; Kaur K; Wadhwa R
J Biol Chem; 2005 Nov; 280(47):39373-9. PubMed ID: 16176931
[TBL] [Abstract][Full Text] [Related]
15. Relevance of mortalin to cancer cell stemness and cancer therapy.
Yun CO; Bhargava P; Na Y; Lee JS; Ryu J; Kaul SC; Wadhwa R
Sci Rep; 2017 Feb; 7():42016. PubMed ID: 28165047
[TBL] [Abstract][Full Text] [Related]
16. Mortalin-p53 interaction in cancer cells is stress dependent and constitutes a selective target for cancer therapy.
Lu WJ; Lee NP; Kaul SC; Lan F; Poon RT; Wadhwa R; Luk JM
Cell Death Differ; 2011 Jun; 18(6):1046-56. PubMed ID: 21233847
[TBL] [Abstract][Full Text] [Related]
17. Mortaparib, a novel dual inhibitor of mortalin and PARP1, is a potential drug candidate for ovarian and cervical cancers.
Putri JF; Bhargava P; Dhanjal JK; Yaguchi T; Sundar D; Kaul SC; Wadhwa R
J Exp Clin Cancer Res; 2019 Dec; 38(1):499. PubMed ID: 31856867
[TBL] [Abstract][Full Text] [Related]
18. In silico analysis of the binding properties of solasonine to mortalin and p53, and in vitro pharmacological studies of its apoptotic and cytotoxic effects on human HepG2 and Hep3b hepatocellular carcinoma cells.
Pham MQ; Tran THV; Pham QL; Gairin JE
Fundam Clin Pharmacol; 2019 Aug; 33(4):385-396. PubMed ID: 30628118
[TBL] [Abstract][Full Text] [Related]
19. Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.
Sane S; Abdullah A; Nelson ME; Wang H; Chauhan SC; Newton SS; Rezvani K
Cell Stress Chaperones; 2016 Mar; 21(2):313-26. PubMed ID: 26634371
[TBL] [Abstract][Full Text] [Related]
20. Targeting Mortalin by Embelin Causes Activation of Tumor Suppressor p53 and Deactivation of Metastatic Signaling in Human Breast Cancer Cells.
Nigam N; Grover A; Goyal S; Katiyar SP; Bhargava P; Wang PC; Sundar D; Kaul SC; Wadhwa R
PLoS One; 2015; 10(9):e0138192. PubMed ID: 26376435
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
